Quanterix (QTRX) reported an insider tax-withholding event by its President & CEO and Director. On October 31, 2025, 254 shares of common stock were withheld at $5.34 to cover taxes upon vesting of 761 RSUs.
After this transaction, the insider beneficially owns 511,442 shares, which includes 219,086 RSUs. The filing reflects routine administration of equity compensation rather than an open‑market sale.
Quanterix (QTRX) insider update: The Chief Financial Officer reported a tax-withholding transaction on 10/15/2025. Code F indicates 229 shares of common stock were withheld at $5.78 per share to satisfy taxes upon vesting of 777 restricted stock units.
Following this non‑open‑market event, the officer beneficially owns 86,742 shares, which includes 70,893 RSUs.
Quanterix Corp (QTRX) disclosed an insider transaction by its President & CEO and Director on 10/15/2025. The filing shows 1,242 shares of common stock were withheld (code F) at $5.78 per share to cover taxes upon the vesting of 3,722 RSUs.
Following this tax-withholding transaction, the reporting person beneficially owns 511,696 shares, which includes 219,847 RSUs. This is an administrative, non‑open market event tied to equity award vesting.
Quanterix Corp (QTRX) disclosed that a director acquired common stock through board compensation. On 10/01/2025, the director received 2,084 shares of common stock granted in lieu of cash fees for service on the Board and its committees for the third quarter of 2025. The grant was valued at the $5.54 closing price on the Nasdaq Global Market on that date.
Following this transaction, the director’s beneficial ownership was 29,488 shares, held directly, which includes 24,464 restricted stock units.
Quanterix Corporation director William P. Donnelly received 5,076 shares of common stock on 10/01/2025 as compensation in lieu of cash for board and committee service for the third quarter of 2025. The shares were recorded at the closing price of $5.54 on the Nasdaq Global Market for that date. Following the grant, Mr. Donnelly beneficially owns 148,374 shares, which include 12,955 restricted stock units. The Form 4 was filed individually and signed via attorney-in-fact on behalf of the reporting person.
Mendel Scott, a director of Quanterix Corp (QTRX), received 2,084 shares of common stock on 10/01/2025 as stock issued in lieu of cash board fees for Q3 2025 at a closing price of $5.54. Following the issuance, Mr. Scott beneficially owns 30,737 shares, which include 24,464 restricted stock units. The Form 4 was signed on behalf of the reporting person by Brian Keane, Attorney-in-Fact. The filing discloses no derivative transactions, option grants, or other cash purchases in this report.
Quanterix Corporation director Walt David R received 2,594 shares of common stock on 10/01/2025 as compensation in lieu of cash for third‑quarter 2025 board and committee fees, at the Nasdaq closing price of $5.54 per share. After the grant, the reporting person beneficially owns 1,871,675 shares, which include 7,435 restricted stock units. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The filing discloses a single non‑derivative acquisition and explains the grant source and price; no options, dispositions, or additional derivative transactions are reported.
Quanterix Corporation reported results from its 2025 Annual Meeting of Stockholders held on September 29, 2025. Stockholders elected Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David R. Walt, Ph.D. to three-year terms on the board of directors, each receiving more than 29.7 million votes in favor.
Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, with about 30.3 million votes for and 5.5 million against. KPMG LLP was ratified as independent registered public accounting firm with over 40.0 million votes for and minimal opposition.
Stockholders backed several governance changes. They approved an amendment to declassify the board of directors and separate amendments to remove supermajority stockholder vote requirements to change certain charter provisions and the company’s bylaws, each receiving approximately 35.6 million votes in favor.
Quanterix Corporation adjourned its shareholder meeting and scheduled an adjourned session for shareholders who pre-register by 10:00am ET on September 28, 2025 at the provided registration URL. The company reported that at the original meeting time shareholders who voted were overwhelmingly in favor of two proposals to eliminate supermajority vote requirements, with 99% of votes cast supporting those two proposals. However, the shares that voted in favor represented 74.8% of the company’s common stock outstanding. The filing is signed by Vandana Sriram, Chief Financial Officer, and lists contact and filing references.
Quanterix Corporation filed an amendment to a current report to provide additional financial details related to its acquisition of Akoya Biosciences, Inc. The acquisition of Akoya was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025 among Quanterix, a merger subsidiary, and Akoya.
This amendment adds unaudited pro forma condensed combined financial statements for Quanterix and Akoya for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025, which are included as Exhibit 99.1. The historical financial statements of Akoya were previously filed in a post-effective amendment to Quanterix’s Form S-4 registration statement and are incorporated by reference rather than repeated here.